Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Feb 28;354(1381):259-68.
doi: 10.1098/rstb.1999.0377.

Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses

Affiliations
Review

Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses

R Pellizzari et al. Philos Trans R Soc Lond B Biol Sci. .

Abstract

The clostridial neurotoxins responsible for tetanus and botulism are proteins consisting of three domains endowed with different functions: neurospecific binding, membrane translocation and proteolysis for specific components of the neuroexocytosis apparatus. Tetanus neurotoxin (TeNT) binds to the presynaptic membrane of the neuromuscular junction, is internalized and transported retroaxonally to the spinal cord. The spastic paralysis induced by the toxin is due to the blockade of neurotransmitter release from spinal inhibitory interneurons. In contrast, the seven serotypes of botulinum neurotoxins (BoNTs) act at the periphery by inducing a flaccid paralysis due to the inhibition of acetylcholine release at the neuromuscular junction. TeNT and BoNT serotypes B, D, F and G cleave specifically at single but different peptide bonds, of the vesicle associated membrane protein (VAMP) synaptobrevin, a membrane protein of small synaptic vesicles (SSVs). BoNT types A, C and E cleave SNAP-25 at different sites located within the carboxyl-terminus, while BoNT type C additionally cleaves syntaxin. The remarkable specificity of BoNTs is exploited in the treatment of human diseases characterized by a hyperfunction of cholinergic terminals.

PubMed Disclaimer

References

    1. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4688-92 - PubMed
    1. Nat Struct Biol. 1998 Oct;5(10):898-902 - PubMed
    1. J Biol Chem. 1996 Mar 29;271(13):7694-9 - PubMed
    1. Infect Immun. 1990 Dec;58(12):4136-41 - PubMed
    1. Eur J Biochem. 1991 Aug 1;199(3):705-11 - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources